APA (7th ed.) Citation

Al Rabadi, L. S., Cook, M. M., Kaempf, A. J., Saraceni, M. M., Savin, M. A., & Mitri, Z. I. (2021). Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab. BMC Cancer, 21(1), 1. https://doi.org/10.1186/s12885-021-08894-2

Chicago Style (17th ed.) Citation

Al Rabadi, Luai S., Madeline M. Cook, Andy J. Kaempf, Megan M. Saraceni, Michael A. Savin, and Zahi I. Mitri. "Ado-trastuzumab for the Treatment of Metastatic HER2-positive Breast Cancer in Patients Previously Treated with Pertuzumab." BMC Cancer 21, no. 1 (2021): 1. https://doi.org/10.1186/s12885-021-08894-2.

MLA (9th ed.) Citation

Al Rabadi, Luai S., et al. "Ado-trastuzumab for the Treatment of Metastatic HER2-positive Breast Cancer in Patients Previously Treated with Pertuzumab." BMC Cancer, vol. 21, no. 1, 2021, p. 1, https://doi.org/10.1186/s12885-021-08894-2.